{"@context":{"@vocab":"https://cir.nii.ac.jp/schema/1.0/","rdfs":"http://www.w3.org/2000/01/rdf-schema#","dc":"http://purl.org/dc/elements/1.1/","dcterms":"http://purl.org/dc/terms/","foaf":"http://xmlns.com/foaf/0.1/","prism":"http://prismstandard.org/namespaces/basic/2.0/","cinii":"http://ci.nii.ac.jp/ns/1.0/","datacite":"https://schema.datacite.org/meta/kernel-4/","ndl":"http://ndl.go.jp/dcndl/terms/","jpcoar":"https://github.com/JPCOAR/schema/blob/master/2.0/"},"@id":"https://cir.nii.ac.jp/crid/1363670320375974656.json","@type":"Article","productIdentifier":[{"identifier":{"@type":"DOI","@value":"10.1038/nbt.1601"}},{"identifier":{"@type":"URI","@value":"http://www.nature.com/articles/nbt.1601.pdf"}},{"identifier":{"@type":"URI","@value":"http://www.nature.com/articles/nbt.1601"}}],"dc:title":[{"@value":"Enhanced antibody half-life improves in vivo activity"}],"creator":[{"@id":"https://cir.nii.ac.jp/crid/1383670320375974656","@type":"Researcher","foaf:name":[{"@value":"Jonathan Zalevsky"}]},{"@id":"https://cir.nii.ac.jp/crid/1383670320375974785","@type":"Researcher","foaf:name":[{"@value":"Aaron K Chamberlain"}]},{"@id":"https://cir.nii.ac.jp/crid/1383670320375974658","@type":"Researcher","foaf:name":[{"@value":"Holly M Horton"}]},{"@id":"https://cir.nii.ac.jp/crid/1383670320375974659","@type":"Researcher","foaf:name":[{"@value":"Sher Karki"}]},{"@id":"https://cir.nii.ac.jp/crid/1383670320375974786","@type":"Researcher","foaf:name":[{"@value":"Irene W L Leung"}]},{"@id":"https://cir.nii.ac.jp/crid/1383670320375974660","@type":"Researcher","foaf:name":[{"@value":"Thomas J Sproule"}]},{"@id":"https://cir.nii.ac.jp/crid/1383670320375974657","@type":"Researcher","foaf:name":[{"@value":"Greg A Lazar"}]},{"@id":"https://cir.nii.ac.jp/crid/1383670320375974784","@type":"Researcher","foaf:name":[{"@value":"Derry C Roopenian"}]},{"@id":"https://cir.nii.ac.jp/crid/1383670320375974787","@type":"Researcher","foaf:name":[{"@value":"John R Desjarlais"}]}],"publication":{"publicationIdentifier":[{"@type":"PISSN","@value":"10870156"},{"@type":"EISSN","@value":"15461696"}],"prism:publicationName":[{"@value":"Nature Biotechnology"}],"dc:publisher":[{"@value":"Springer Science and Business Media LLC"}],"prism:publicationDate":"2010-01-17","prism:volume":"28","prism:number":"2","prism:startingPage":"157","prism:endingPage":"159"},"reviewed":"false","dc:rights":["http://www.springer.com/tdm"],"url":[{"@id":"http://www.nature.com/articles/nbt.1601.pdf"},{"@id":"http://www.nature.com/articles/nbt.1601"}],"createdAt":"2010-01-17","modifiedAt":"2025-02-16","relatedProduct":[{"@id":"https://cir.nii.ac.jp/crid/1360004233411851392","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"The TWEAK Receptor Fn14 Is a Therapeutic Target in Melanoma: Immunotoxins Targeting Fn14 Receptor for Malignant Melanoma Treatment"}]},{"@id":"https://cir.nii.ac.jp/crid/1360009142649046656","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"The influence of antibody engineering on Fc conformation and Fc receptor binding properties: Analysis of FcRn-binding engineered antibodies and an Fc fusion protein"}]},{"@id":"https://cir.nii.ac.jp/crid/1360294643847474688","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Suppression of Rheumatoid Arthritis by Enhanced Lymph Node Trafficking of Engineered Interleukin‐10 in Murine Models"}]},{"@id":"https://cir.nii.ac.jp/crid/1360567182283851008","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"T-Cell mediated adaptive immunity and antibody-dependent enhancement in secondary dengue infection"}]},{"@id":"https://cir.nii.ac.jp/crid/1360848660865852416","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Intracellular Dynamics and Fate of a Humanized Anti–Interleukin-6 Receptor Monoclonal Antibody, Tocilizumab"}]},{"@id":"https://cir.nii.ac.jp/crid/1360861289349628800","@type":"Article","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Physiologically based pharmacokinetic (PBPK) model that describes enhanced FcRn-dependent distribution of monoclonal antibodies (mAbs) by pI-engineering in mice"}]},{"@id":"https://cir.nii.ac.jp/crid/1361134273560587904","@type":"Article","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Quantitative prediction of therapeutic antibody pharmacokinetics after intravenous and subcutaneous injection in human"}]},{"@id":"https://cir.nii.ac.jp/crid/1362541648444371840","@type":"Article","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Improvement of pharmacokinetic properties of therapeutic antibodies by antibody engineering"}]},{"@id":"https://cir.nii.ac.jp/crid/1390282679252030080","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"FcRn, a critical regulator of antibody pharmacokinetics"},{"@language":"ja","@value":"抗体医薬品の体内動態制御に関わる受容体：ＦｃＲｎ"},{"@language":"ja-Kana","@value":"コウタイ イヤクヒン ノ タイナイ ドウタイ セイギョ ニ カカワル ジュヨウタイ FcRn"}]},{"@id":"https://cir.nii.ac.jp/crid/1390282681103879680","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"ja","@value":"次世代抗体医薬品の非臨床評価"},{"@language":"en","@value":"Nonclinical Evaluation of Next-generation Therapeutic Monoclonal Antibodies"},{"@value":"Symposium Review 次世代抗体医薬品の非臨床評価"},{"@language":"ja-Kana","@value":"Symposium Review ジセダイ コウタイ イヤクヒン ノ ヒリンショウ ヒョウカ"}]}],"dataSourceIdentifier":[{"@type":"CROSSREF","@value":"10.1038/nbt.1601"},{"@type":"CROSSREF","@value":"10.1080/19420862.2021.1923366_references_DOI_SYU2TlDPnO3zg4LGKclxlb1XzME"},{"@type":"CROSSREF","@value":"10.1248/yakushi.15-00007-3_references_DOI_SYU2TlDPnO3zg4LGKclxlb1XzME"},{"@type":"CROSSREF","@value":"10.1002/art.41585_references_DOI_SYU2TlDPnO3zg4LGKclxlb1XzME"},{"@type":"CROSSREF","@value":"10.1038/jid.2012.402_references_DOI_SYU2TlDPnO3zg4LGKclxlb1XzME"},{"@type":"CROSSREF","@value":"10.1254/fpj.136.280_references_DOI_SYU2TlDPnO3zg4LGKclxlb1XzME"},{"@type":"CROSSREF","@value":"10.1124/mol.115.099184_references_DOI_SYU2TlDPnO3zg4LGKclxlb1XzME"},{"@type":"CROSSREF","@value":"10.1016/j.dmpk.2023.100506_references_DOI_SYU2TlDPnO3zg4LGKclxlb1XzME"},{"@type":"CROSSREF","@value":"10.1016/j.dmpk.2017.05.002_references_DOI_SYU2TlDPnO3zg4LGKclxlb1XzME"},{"@type":"CROSSREF","@value":"10.1016/j.jtbi.2019.03.010_references_DOI_SYU2TlDPnO3zg4LGKclxlb1XzME"},{"@type":"CROSSREF","@value":"10.1016/j.dmpk.2018.10.003_references_DOI_SYU2TlDPnO3zg4LGKclxlb1XzME"}]}